70110-45-1 Usage
General Description
3-Benzyl-3-azabicyclo[3.1.0]hexane is a chemical compound also known as 3-benzyl-3-azabicyclo[3.1.0]hexane. It is a bicyclic compound with a nitrogen atom in the ring, and a benzene ring attached to one of the carbon atoms. 3-Benzyl-3-azabicyclo[3.1.0]hexane has potential applications in medicinal chemistry and drug design, as it can be used to create new drug molecules with specific pharmacological properties. It is also used as a building block in organic synthesis, enabling the production of various other chemical compounds. Furthermore, 3-Benzyl-3-azabicyclo[3.1.0]hexane has been studied for its potential biological activities, including its role as a potential antiviral and antibacterial agent. Overall, this chemical compound has diverse uses and potential applications in various fields of research and industry.
Check Digit Verification of cas no
The CAS Registry Mumber 70110-45-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,0,1,1 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 70110-45:
(7*7)+(6*0)+(5*1)+(4*1)+(3*0)+(2*4)+(1*5)=71
71 % 10 = 1
So 70110-45-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H15N/c1-2-4-10(5-3-1)7-13-8-11-6-12(11)9-13/h1-5,11-12H,6-9H2
70110-45-1Relevant articles and documents
PLASMA KALLIKREIN INHIBITORS
-
, (2022/01/05)
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
-
Paragraph 0200, (2016/11/21)
Provided are certain histone deacetylase (HDAC) inhibitors of Formula (I), compositions thereof, and methods of their use.
IMIDAZOPYRIDAZINE COMPOUNDS
-
Paragraph 0337-0338, (2013/05/09)
The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
